<?xml version='1.0' encoding='utf-8'?>
<document id="20562093"><sentence text="Pharmacokinetics and dose recommendations of Niaspan速 in chronic kidney disease and dialysis patients." /><sentence text="Niaspan速 is an extended-release formulation of nicotinic acid with improved tolerability compared with the immediate-release and sustained-release formulations"><entity charOffset="47-61" id="DDI-PubMed.20562093.s2.e0" text="nicotinic acid" /></sentence><sentence text=" It is used to treat hypertriglyceridaemia with low high-density lipoprotein levels" /><sentence text=" This type of dyslipidaemia frequently appears in patients with chronic kidney disease (CKD)" /><sentence text=" Dose recommendations for these patients are not available because pharmacokinetic data are missing" /><sentence text=" The present study was performed to analyse the pharmacokinetics of prolonged-release nicotinic acid in CKD and in dialysis patients to derive dose recommendations"><entity charOffset="86-100" id="DDI-PubMed.20562093.s6.e0" text="nicotinic acid" /></sentence><sentence text="" /><sentence text="Ten dialysis patients and eight patients with CKD were enrolled in a prospective, three-period, open-label pharmacokinetic study" /><sentence text=" They received in the first week 500 mg Niaspan速 per day, in the second week 1000 mg/day and in the third week 1500 mg/day" /><sentence text=" On the fourth day of every treatment unit, 11 plasma samples were collected for 24 h post-dose and analysed for nicotinic acid (NA) and its metabolites nicotinamide and nicotinuric acid (NUA)"><entity charOffset="113-127" id="DDI-PubMed.20562093.s10.e0" text="nicotinic acid" /><entity charOffset="129-131" id="DDI-PubMed.20562093.s10.e1" text="NA" /><entity charOffset="153-165" id="DDI-PubMed.20562093.s10.e2" text="nicotinamide" /><entity charOffset="170-186" id="DDI-PubMed.20562093.s10.e3" text="nicotinuric acid" /><entity charOffset="188-191" id="DDI-PubMed.20562093.s10.e4" text="NUA" /><pair ddi="false" e1="DDI-PubMed.20562093.s10.e0" e2="DDI-PubMed.20562093.s10.e0" /><pair ddi="false" e1="DDI-PubMed.20562093.s10.e0" e2="DDI-PubMed.20562093.s10.e1" /><pair ddi="false" e1="DDI-PubMed.20562093.s10.e0" e2="DDI-PubMed.20562093.s10.e2" /><pair ddi="false" e1="DDI-PubMed.20562093.s10.e0" e2="DDI-PubMed.20562093.s10.e3" /><pair ddi="false" e1="DDI-PubMed.20562093.s10.e0" e2="DDI-PubMed.20562093.s10.e4" /><pair ddi="false" e1="DDI-PubMed.20562093.s10.e1" e2="DDI-PubMed.20562093.s10.e1" /><pair ddi="false" e1="DDI-PubMed.20562093.s10.e1" e2="DDI-PubMed.20562093.s10.e2" /><pair ddi="false" e1="DDI-PubMed.20562093.s10.e1" e2="DDI-PubMed.20562093.s10.e3" /><pair ddi="false" e1="DDI-PubMed.20562093.s10.e1" e2="DDI-PubMed.20562093.s10.e4" /><pair ddi="false" e1="DDI-PubMed.20562093.s10.e2" e2="DDI-PubMed.20562093.s10.e2" /><pair ddi="false" e1="DDI-PubMed.20562093.s10.e2" e2="DDI-PubMed.20562093.s10.e3" /><pair ddi="false" e1="DDI-PubMed.20562093.s10.e2" e2="DDI-PubMed.20562093.s10.e4" /><pair ddi="false" e1="DDI-PubMed.20562093.s10.e3" e2="DDI-PubMed.20562093.s10.e3" /><pair ddi="false" e1="DDI-PubMed.20562093.s10.e3" e2="DDI-PubMed.20562093.s10.e4" /></sentence><sentence text="" /><sentence text="Median plasma NA concentrations in subjects with CKD were obviously higher than in dialysis patients, but not higher than reported in patients without renal impairment"><entity charOffset="14-16" id="DDI-PubMed.20562093.s12.e0" text="NA" /></sentence><sentence text=" t(max) of NA were on average 0"><entity charOffset="11-12" id="DDI-PubMed.20562093.s13.e0" text="NA" /></sentence><sentence text="75 h in dialysis patients and 3" /><sentence text="0 h in CKD patients and, therefore, especially for dialysis patients, clearly shorter than expected for extended-release formulations" /><sentence text=" It is particularly noticeable that the AUC, C(max) and t(1/2) of the metabolite NUA are significantly higher in dialysis patients in comparison to CKD patients"><entity charOffset="81-82" id="DDI-PubMed.20562093.s16.e0" text="NUA" /></sentence><sentence text=" This may indicate that the dialysis was not effective in removing this metabolite" /><sentence text=" However, there was no correlation between the incidence of flush and the concentration of NUA"><entity charOffset="91-93" id="DDI-PubMed.20562093.s18.e0" text="NUA" /></sentence><sentence text=" Another possibility could be a drug-drug interaction with omeprazole via CYP450 enzymes"><entity charOffset="59-69" id="DDI-PubMed.20562093.s19.e0" text="omeprazole" /></sentence><sentence text="" /><sentence text="These data suggest that no dose adjustment of Niaspan速 is necessary in patients with renal impairment"><entity charOffset="46-53" id="DDI-PubMed.20562093.s21.e0" text="Niaspan" /></sentence><sentence text=" Despite an extended-release formulation of NA, we could not detect a delay in t(max) especially in dialysis patients"><entity charOffset="44-46" id="DDI-PubMed.20562093.s22.e0" text="NA" /></sentence><sentence text=" We found no correlation between the incidence of flush and the NUA concentration"><entity charOffset="64-65" id="DDI-PubMed.20562093.s23.e0" text="NUA" /></sentence><sentence text=" Furthermore, there were hints of an interaction with omeprazole"><entity charOffset="54-64" id="DDI-PubMed.20562093.s24.e0" text="omeprazole" /></sentence><sentence text="" /></document>